{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:37:28Z","timestamp":1792849048138,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"KPK InVite Baden-W\u00fcrttemberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Early detection and understanding of the potential adverse effects of a drug candidate is of utmost importance to reduce the attrition rate during drug development while delivering safe medications to patients. The kidney is one of the most frequently challenged organs involved in drug-induced toxicity, including general glomerulopathy and podocyte- specific cytotoxicity with ensuing overt proteinuria. Whilst TEAD inhibitors address the need for treatment of mesotheliomas and other tumours unaffected by approved drugs, animal testing and clinical trials provide evidence of renal toxicity induced by this novel class of drugs. Here we present an in vitro test system consisting of immortalized human podocytes PODO\/TERT256 to characterize the potential adverse effects of TEAD inhibitors. We demonstrate that TEAD inhibitors K-975, IK-930 and VT-107 affect the podocyte monolayer in a wide dose range (33.3\u2013100 \u00b5M), disrupt the cellular vesicle system, and subsequently induce cell death, especially after exposure to pan-TEAD inhibitors (VT-107 and K-975). Of note, low micromolar concentrations of TEAD inhibitors lowered mitochondrial oxidative phosphorylation directly after exposure which was confirmed by reduced basal ATP levels after 3 d of exposure. In summary, the in vitro human podocyte model presented can characterize glomerular filtration functionality decline subsequent to TEAD inhibitor exposure and thus represents a promising model for early detection and prediction of potential drug related glomerulopathy in humans.<\/jats:p>","DOI":"10.1007\/s00204-026-04497-7","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:28:59Z","timestamp":1784035739000},"page":"5181-5194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TEAD inhibitor induced switch in energy metabolism drives human podocyte injury in vitro"],"prefix":"10.1007","volume":"100","author":[{"given":"Alexander","family":"Zielinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hauptstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Baier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schaarschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ketter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"5","key":"4497_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.23876\/j.krcp.22.233","volume":"42","author":"J Baek","year":"2023","unstructured":"Baek J, Lee YH, Jeong HY, Lee SY (2023) Mitochondrial quality control and its emerging role in the pathogenesis of diabetic kidney disease. Kidney Res Clin Pract 42(5):546\u2013560. https:\/\/doi.org\/10.23876\/j.krcp.22.233","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"4497_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z et al (2000) The protein data bank. Nucleic Acids Res 28(1):235\u2013242. https:\/\/doi.org\/10.1093\/nar\/28.1.235","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4497_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.celrep.2019.04.012","volume":"27","author":"PT Brinkkoetter","year":"2019","unstructured":"Brinkkoetter PT, Bork T, Salou S et al (2019) Anaerobic glycolysis maintains the glomerular filtration barrier independent of mitochondrial metabolism and dynamics. Cell Rep 27(5):1551\u20131566e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.012","journal-title":"Cell Rep"},{"issue":"7","key":"4497_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA, Sansregret L, Galli GG et al (2024) Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers. Nat Cancer 5(7):1102\u20131120. https:\/\/doi.org\/10.1038\/s43018-024-00754-9","journal-title":"Nat Cancer"},{"key":"4497_CR5","doi-asserted-by":"publisher","unstructured":"Chen H, Gridnev A, Schlamowitz N et al (2024) Targeted degradation of specific TEAD paralogs by small molecule degraders. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37829","DOI":"10.1016\/j.heliyon.2024.e37829"},{"issue":"3","key":"4497_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1517\/17425255.2013.741589","volume":"9","author":"X Chu","year":"2013","unstructured":"Chu X, Bleasby K, Evers R (2013) Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 9(3):237\u2013252. https:\/\/doi.org\/10.1517\/17425255.2013.741589","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"4497_CR7","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/s41598-017-04580-1","volume":"7","author":"MO Collins","year":"2017","unstructured":"Collins MO, Woodley KT, Choudhary JS (2017) Global, site-specific analysis of neuronal protein S-acylation. Sci Rep 7(1):4683. https:\/\/doi.org\/10.1038\/s41598-017-04580-1","journal-title":"Sci Rep"},{"issue":"4","key":"4497_CR8","doi-asserted-by":"publisher","first-page":"tfae119","DOI":"10.1093\/toxres\/tfae119","volume":"13","author":"S Connor","year":"2024","unstructured":"Connor S, Roberts RA, Tong W (2024) Drug-induced kidney injury: challenges and opportunities. Toxicol Res (Camb) 13(4):tfae119. https:\/\/doi.org\/10.1093\/toxres\/tfae119","journal-title":"Toxicol Res (Camb)"},{"issue":"3","key":"4497_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/cs20201474","volume":"136","author":"R Cunningham","year":"2022","unstructured":"Cunningham R, Hansen Carsten G (2022) The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets in cancer. Clin Sci 136(3):197\u2013222. https:\/\/doi.org\/10.1042\/cs20201474","journal-title":"Clin Sci"},{"key":"4497_CR10","doi-asserted-by":"publisher","unstructured":"Cunningham R, Jia S, Purohit K et al (2025) Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma. Life Sci Alliance. https:\/\/doi.org\/10.26508\/lsa.202503241","DOI":"10.26508\/lsa.202503241"},{"issue":"11","key":"4497_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41573-025-01234-0","volume":"24","author":"KF Harvey","year":"2025","unstructured":"Harvey KF, Tang TT (2025) Targeting the Hippo pathway in cancer. Nat Rev Drug Discovery 24(11):852\u2013869. https:\/\/doi.org\/10.1038\/s41573-025-01234-0","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"4497_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13(4):246\u2013257. https:\/\/doi.org\/10.1038\/nrc3458","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4497_CR13","doi-asserted-by":"publisher","first-page":"45465","DOI":"10.1038\/srep45465","volume":"7","author":"S Heinz","year":"2017","unstructured":"Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H (2017) Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. Sci Rep 7(1):45465. https:\/\/doi.org\/10.1038\/srep45465","journal-title":"Sci Rep"},{"issue":"9","key":"4497_CR14","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/nprot.2007.303","volume":"2","author":"I Hubatsch","year":"2007","unstructured":"Hubatsch I, Ragnarsson EGE, Artursson P (2007) Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2(9):2111\u20132119. https:\/\/doi.org\/10.1038\/nprot.2007.303","journal-title":"Nat Protoc"},{"issue":"9","key":"4497_CR15","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.biocel.2013.06.013","volume":"45","author":"T Imasawa","year":"2013","unstructured":"Imasawa T, Rossignol R (2013) Podocyte energy metabolism and glomerular diseases. Int J Biochem Cell Biol 45(9):2109\u20132118. https:\/\/doi.org\/10.1016\/j.biocel.2013.06.013","journal-title":"Int J Biochem Cell Biol"},{"key":"4497_CR16","doi-asserted-by":"publisher","unstructured":"Kakiuchi-Kiyota S, Schutten MM, Zhong Y, Crawford JJ, Dey A (2019) Safety Considerations in the Development of Hippo Pathway Inhibitors in Cancers. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2019.00156","DOI":"10.3389\/fcell.2019.00156"},{"issue":"12","key":"4497_CR17","first-page":"4399","volume":"10","author":"A Kaneda","year":"2020","unstructured":"Kaneda A, Seike T, Danjo T et al (2020) The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am J Cancer Res 10(12):4399\u20134415","journal-title":"Am J Cancer Res"},{"issue":"1","key":"4497_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41467-017-02655-1","volume":"9","author":"RS Kathayat","year":"2018","unstructured":"Kathayat RS, Cao Y, Elvira PD et al (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9(1):334. https:\/\/doi.org\/10.1038\/s41467-017-02655-1","journal-title":"Nat Commun"},{"issue":"1","key":"4497_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","volume":"6","author":"JB Kopp","year":"2020","unstructured":"Kopp JB, Anders H-J, Susztak K et al (2020) Podocytopathies. Nat Rev Disease Primers 6(1):68. https:\/\/doi.org\/10.1038\/s41572-020-0196-7","journal-title":"Nat Reviews Disease Primers"},{"issue":"4","key":"4497_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00204-013-1038-0","volume":"87","author":"M Leist","year":"2013","unstructured":"Leist M, Hartung T (2013) Inflammatory findings on species extrapolations: humans are definitely 70-kg mice. Arch Toxicol 87(4):563\u2013567. https:\/\/doi.org\/10.1007\/s00204-013-1038-0","journal-title":"Arch Toxicol"},{"issue":"3","key":"4497_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1101\/gad.1865810","volume":"24","author":"Z Li","year":"2010","unstructured":"Li Z, Zhao B, Wang P et al (2010) Structural insights into the YAP and TEAD complex. Genes Dev 24(3):235\u2013240. https:\/\/doi.org\/10.1101\/gad.1865810","journal-title":"Genes Dev"},{"issue":"5","key":"4497_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1021\/acsmedchemlett.4c00029","volume":"15","author":"H Li","year":"2024","unstructured":"Li H, Ge Z, Lin K et al (2024) Design, synthesis, and bioevaluation of transcriptional enhanced assocciated domain (TEAD) PROTAC degraders. ACS Med Chem Lett 15(5):631\u2013639. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00029","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"4497_CR23","doi-asserted-by":"publisher","first-page":"H89","DOI":"10.1152\/ajpheart.00732.2019","volume":"319","author":"R Liu","year":"2020","unstructured":"Liu R, Jagannathan R, Sun L et al (2020) Tead1 is essential for mitochondrial function in cardiomyocytes. Am J Physiol Heart Circ Physiol 319(1):H89\u2013h99. https:\/\/doi.org\/10.1152\/ajpheart.00732.2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4497_CR24","doi-asserted-by":"publisher","first-page":"114847","DOI":"10.1016\/j.ejmech.2022.114847","volume":"244","author":"M Luo","year":"2022","unstructured":"Luo M, Xu Y, Chen H et al (2022) Advances of targeting the YAP\/TAZ-TEAD complex in the hippo pathway for the treatment of cancers. Eur J Med Chem 244:114847. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114847","journal-title":"Eur J Med Chem"},{"issue":"11","key":"4497_CR25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/j.1460-2075.1982.tb01321.x","volume":"1","author":"B Maro","year":"1982","unstructured":"Maro B, Marty MC, Bornens M (1982) In vivo and in vitro effects of the mitochondrial uncoupler FCCP on microtubules. Embo j 1(11):1347\u20131352. https:\/\/doi.org\/10.1002\/j.1460-2075.1982.tb01321.x","journal-title":"Embo j"},{"issue":"2","key":"4497_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/138620710790596736","volume":"13","author":"JM McKim Jr","year":"2010","unstructured":"McKim JM Jr (2010) Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with. Vivo Relevance Comb Chem High Throughput Screen 13(2):188\u2013206. https:\/\/doi.org\/10.2174\/138620710790596736","journal-title":"Vivo Relevance Comb Chem High Throughput Screen"},{"issue":"51","key":"4497_CR27","doi-asserted-by":"publisher","first-page":"21137","DOI":"10.1074\/jbc.M117.819029","volume":"292","author":"K Meliambro","year":"2017","unstructured":"Meliambro K, Wong JS, Ray J et al (2017) The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics. J Biol Chem 292(51):21137\u201321148. https:\/\/doi.org\/10.1074\/jbc.M117.819029","journal-title":"J Biol Chem"},{"key":"4497_CR28","unstructured":"NanoLive (2019) Cell drinking: a closer look on macropinocytosis. In. https:\/\/www.nanolive.com\/cell-drinking-a-closer-look-on-macropinocytosis\/ Accessed January 17, 2026"},{"issue":"5","key":"4497_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","volume":"5","author":"CDK Nguyen","year":"2019","unstructured":"Nguyen CDK, Yi C (2019) YAP\/TAZ Signaling and resistance to cancer therapy. Trends Cancer 5(5):283\u2013296. https:\/\/doi.org\/10.1016\/j.trecan.2019.02.010","journal-title":"Trends Cancer"},{"issue":"1","key":"4497_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.str.2015.11.00","volume":"24","author":"CL Noland","year":"2016","unstructured":"Noland CL, Gierke S, Schnier PD et al (2016) Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway signaling. Structure 24(1):179\u2013186. https:\/\/doi.org\/10.1016\/j.str.2015.11.00","journal-title":"Structure"},{"issue":"4","key":"4497_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1021\/acschembio.5c00162","volume":"20","author":"K Nutsch","year":"2025","unstructured":"Nutsch K, Trujillo MN, Song L et al (2025) Augmented Acyl-CoA biosynthesis promotes resistance to TEAD palmitoylation site inhibition. ACS Chem Biol 20(4):967\u2013975. https:\/\/doi.org\/10.1021\/acschembio.5c00162","journal-title":"ACS Chem Biol"},{"issue":"1","key":"4497_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","volume":"32","author":"H Olson","year":"2000","unstructured":"Olson H, Betton G, Robinson D et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1):56\u201367. https:\/\/doi.org\/10.1006\/rtph.2000.1399","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"4497_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2131\/jts.49.175","volume":"49","author":"H Otsuki","year":"2024","unstructured":"Otsuki H, Uemori T, Inai Y et al (2024) Reversible and monitorable nephrotoxicity in rats by the novel potent transcriptional enhanced associate domain (TEAD) inhibitor, K-975. J Toxicol Sci 49(4):175\u2013191. https:\/\/doi.org\/10.2131\/jts.49.175","journal-title":"J Toxicol Sci"},{"issue":"1","key":"4497_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.trecan.2024.10.004","volume":"11","author":"S Paul","year":"2025","unstructured":"Paul S, Sims J, Pham T, Dey A (2025) Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors? Trends Cancer 11(1):25\u201336. https:\/\/doi.org\/10.1016\/j.trecan.2024.10.004","journal-title":"Trends Cancer"},{"issue":"1","key":"4497_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00020.2002","volume":"83","author":"H Pavenstadt","year":"2003","unstructured":"Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83(1):253\u2013307. https:\/\/doi.org\/10.1152\/physrev.00020.2002","journal-title":"Physiol Rev"},{"issue":"5","key":"4497_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","volume":"48","author":"AV Pobbati","year":"2023","unstructured":"Pobbati AV, Kumar R, Rubin BP, Hong W (2023) Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem Sci 48(5):450\u2013462. https:\/\/doi.org\/10.1016\/j.tibs.2022.12.005","journal-title":"Trends Biochem Sci"},{"issue":"11","key":"4497_CR36","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","volume":"23","author":"V Pobbati Ajaybabu","year":"2015","unstructured":"Pobbati Ajaybabu V, Han X, Hung Alvin W et al (2015) Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure 23(11):2076\u20132086. https:\/\/doi.org\/10.1016\/j.str.2015.09.009","journal-title":"Structure"},{"issue":"1","key":"4497_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.taap.2009.07.027","volume":"241","author":"S Schildknecht","year":"2009","unstructured":"Schildknecht S, P\u00f6ltl D, Nagel DM et al (2009) Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmcol 241(1):23\u201335. https:\/\/doi.org\/10.1016\/j.taap.2009.07.027","journal-title":"Toxicol Appl Pharmcol"},{"key":"4497_CR39","doi-asserted-by":"publisher","first-page":"110813","DOI":"10.1016\/j.cbi.2023.110813","volume":"387","author":"N Schlichenmaier","year":"2024","unstructured":"Schlichenmaier N, Zielinski A, Beneke S, Dietrich DR (2024) PODO\/TERT256: a promising human immortalized podocyte cell line and its potential use for in vitro research at different oxygen levels. Chemico-Biol Interact 387:110813. https:\/\/doi.org\/10.1016\/j.cbi.2023.110813","journal-title":"Chemico-Biol Interact"},{"issue":"7","key":"4497_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089","journal-title":"Nat Methods"},{"issue":"2","key":"4497_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41419-018-0273-y","volume":"9","author":"PF Secker","year":"2018","unstructured":"Secker PF, Beneke S, Schlichenmaier N et al (2018) Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Cell Death Dis 9(2):226. https:\/\/doi.org\/10.1038\/s41419-018-0273-y","journal-title":"Cell Death Dis"},{"issue":"W1","key":"4497_CR42","doi-asserted-by":"publisher","first-page":"W431","DOI":"10.1093\/nar\/gkab314","volume":"49","author":"D Sehnal","year":"2021","unstructured":"Sehnal D, Bittrich S, Deshpande M et al (2021) Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids Res 49(W1):W431\u2013W437. https:\/\/doi.org\/10.1093\/nar\/gkab314","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"4497_CR43","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/sj.ki.5000410","volume":"69","author":"SJ Shankland","year":"2006","unstructured":"Shankland SJ (2006) The podocyte\u2019s response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 69(12):2131\u20132147. https:\/\/doi.org\/10.1038\/sj.ki.5000410","journal-title":"Kidney Int"},{"issue":"53","key":"4497_CR44","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.1038\/sj.onc.1206053","volume":"21","author":"LA Shchepina","year":"2002","unstructured":"Shchepina LA, Pletjushkina OY, Avetisyan AV et al (2002) Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis. Oncogene 21(53):8149\u20138157. https:\/\/doi.org\/10.1038\/sj.onc.1206053","journal-title":"Oncogene"},{"issue":"1","key":"4497_CR45","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41598-017-02159-4","volume":"7","author":"L-F Shen","year":"2017","unstructured":"Shen L-F, Chen Y-J, Liu K-M et al (2017) Role of S-Palmitoylation by ZDHHC13 in Mitochondrial function and metabolism in liver. Sci Rep 7(1):2182. https:\/\/doi.org\/10.1038\/s41598-017-02159-4","journal-title":"Sci Rep"},{"issue":"4","key":"4497_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jemt.10082","volume":"57","author":"I Shirato","year":"2002","unstructured":"Shirato I (2002) Podocyte process effacement in vivo. Microsc Res Tech 57(4):241\u2013246. https:\/\/doi.org\/10.1002\/jemt.10082","journal-title":"Microsc Res Tech"},{"issue":"34","key":"4497_CR47","doi-asserted-by":"publisher","first-page":"55863","DOI":"10.18632\/oncotarget.10150","volume":"7","author":"AV Shubin","year":"2016","unstructured":"Shubin AV, Demidyuk IV, Komissarov AA, Rafieva LM, Kostrov SV (2016) Cytoplasmic vacuolization in cell death and survival. Oncotarget 7(34):55863. https:\/\/doi.org\/10.18632\/oncotarget.10150","journal-title":"Oncotarget"},{"issue":"1","key":"4497_CR48","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/s41467-022-34559-0","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun Y, Hu L, Tao Z et al (2022) Pharmacological blockade of TEAD\u2013YAP reveals its therapeutic limitation in cancer cells. Nat Commun 13(1):6744. https:\/\/doi.org\/10.1038\/s41467-022-34559-0","journal-title":"Nat Commun"},{"issue":"1","key":"4497_CR49","doi-asserted-by":"publisher","first-page":"9977","DOI":"10.1038\/s41467-024-54222-0","volume":"15","author":"M Takahashi","year":"2024","unstructured":"Takahashi M, Yamamoto S, Yamamoto S et al (2024) ATP dynamics as a predictor of future podocyte structure and function after acute ischemic kidney injury in female mice. Nat Commun 15(1):9977. https:\/\/doi.org\/10.1038\/s41467-024-54222-0","journal-title":"Nat Commun"},{"issue":"6","key":"4497_CR50","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/1535-7163.Mct-20-0717","volume":"20","author":"TT Tang","year":"2021","unstructured":"Tang TT, Konradi AW, Feng Y et al (2021) Small Molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. Mol Cancer Ther 20(6):986\u2013998. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0717","journal-title":"Mol Cancer Ther"},{"key":"4497_CR51","doi-asserted-by":"publisher","first-page":"801837","DOI":"10.3389\/fmed.2022.801837","volume":"9","author":"X Tian","year":"2022","unstructured":"Tian X, Bunda P, Ishibe S (2022) Podocyte endocytosis in regulating the glomerular filtration barrier. Front Med (Lausanne) 9:801837. https:\/\/doi.org\/10.3389\/fmed.2022.801837","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"4497_CR52","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1021\/mp400720w","volume":"11","author":"HY Tiong","year":"2014","unstructured":"Tiong HY, Huang P, Xiong S, Li Y, Vathsala A, Zink D (2014) Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharm 11(7):1933\u20131948. https:\/\/doi.org\/10.1021\/mp400720w","journal-title":"Mol Pharm"},{"issue":"16suppl","key":"4497_CR53","doi-asserted-by":"publisher","first-page":"TPS3168","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","volume":"40","author":"AW Tolcher","year":"2022","unstructured":"Tolcher AW, Lakhani NJ, McKean M et al (2022) A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors. J Clin Oncol 40(16suppl):TPS3168\u2013TPS3168. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS3168","journal-title":"J Clin Oncol"},{"issue":"2","key":"4497_CR54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.7150\/ijbs.104335","volume":"21","author":"M Tran","year":"2025","unstructured":"Tran M, Jiao B, Du H, Zhou D, Yechoor V, Wang Y (2025) TEAD1 prevents necroptosis and inflammation in cisplatin-induced acute kidney injury through maintaining mitochondrial function. Int J Biol Sci 21(2):565\u2013578. https:\/\/doi.org\/10.7150\/ijbs.104335","journal-title":"Int J Biol Sci"},{"key":"4497_CR55","doi-asserted-by":"publisher","first-page":"102563","DOI":"10.1016\/j.ceb.2025.102563","volume":"95","author":"H Tu","year":"2025","unstructured":"Tu H, Wang H, Cai H (2025) Macropinocytosis: molecular mechanisms and regulation. Curr Opin Cell Biol 95:102563. https:\/\/doi.org\/10.1016\/j.ceb.2025.102563","journal-title":"Curr Opin Cell Biol"},{"key":"4497_CR56","unstructured":"Vivace Therapeutics I (2025) Vivace therapeutics\u2019 VT3989 granted fast track designation by the U.S. food and drug administration for the treatment of mesothelioma In. Accessed January 16, 2026 https:\/\/www.prnewswire.com\/news-releases\/vivace-therapeutics-vt3989-granted-fast-track-designation-by-the-us-food-and-drug-administration-for-the-treatment-of-mesothelioma-302577269.html Accessed January 16, 2026"},{"key":"4497_CR57","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.bios.2015.10.027","volume":"77","author":"Y Xu","year":"2016","unstructured":"Xu Y, Xie X, Duan Y, Wang L, Cheng Z, Cheng J (2016) A review of impedance measurements of whole cells. Biosens Bioelectron 77:824\u2013836. https:\/\/doi.org\/10.1016\/j.bios.2015.10.027","journal-title":"Biosens Bioelectron"},{"issue":"11","key":"4497_CR58","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1016\/j.jtho.2023.09.680","volume":"18","author":"T Yap","year":"2023","unstructured":"Yap T, Desai J, Dagogo-Jack I et al (2023a) P2.19-01 first-in-human phase 1 trial of VT3989, a first-in-class YAP\/TEAD inhibitor in patients with advanced mesothelioma. J Thorac Oncol 18(11):S384. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.680","journal-title":"J Thorac Oncol"},{"issue":"8Supplement","key":"4497_CR59","doi-asserted-by":"publisher","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","volume":"83","author":"TA Yap","year":"2023","unstructured":"Yap TA, Kwiatkowski DJ, Desai J et al (2023b) Abstract CT006: first-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. Cancer Res 83(8Supplement):CT006\u2013CT006","journal-title":"Cancer Res"},{"issue":"7Supplement","key":"4497_CR60","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/1538-7445.Am2023-1646","volume":"83","author":"N Young","year":"2023","unstructured":"Young N, Punkosdy G, Cavanaugh J et al (2023) Abstract 1646: IK-930, a paralog-selective TEAD inhibitor for treating YAP\/TAZ-TEAD dependent cancers. Cancer Res 83(7Supplement):1646\u20131646. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-1646","journal-title":"Cancer Res"},{"issue":"6","key":"4497_CR61","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.trecan.2019.04.002","volume":"5","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Commisso C (2019) Macropinocytosis in cancer: a complex signaling network. Trends Cancer 5(6):332\u2013334. https:\/\/doi.org\/10.1016\/j.trecan.2019.04.002","journal-title":"Trends Cancer"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04497-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:01:38Z","timestamp":1792846898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04497-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4497"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04497-7","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}